192 related articles for article (PubMed ID: 25943792)
1. Adverse Outcome Pathways can drive non-animal approaches for safety assessment.
Burden N; Sewell F; Andersen ME; Boobis A; Chipman JK; Cronin MT; Hutchinson TH; Kimber I; Whelan M
J Appl Toxicol; 2015 Sep; 35(9):971-5. PubMed ID: 25943792
[TBL] [Abstract][Full Text] [Related]
2. Aligning the 3Rs with new paradigms in the safety assessment of chemicals.
Burden N; Mahony C; Müller BP; Terry C; Westmoreland C; Kimber I
Toxicology; 2015 Apr; 330():62-6. PubMed ID: 25932488
[TBL] [Abstract][Full Text] [Related]
3. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
[TBL] [Abstract][Full Text] [Related]
4. Uncertainty of testing methods--what do we (want to) know?
Paparella M; Daneshian M; Hornek-Gausterer R; Kinzl M; Mauritz I; Mühlegger S
ALTEX; 2013; 30(2):131-44. PubMed ID: 23665803
[TBL] [Abstract][Full Text] [Related]
5. Validation of innovative technologies and strategies for regulatory safety assessment methods: challenges and opportunities.
Stokes WS; Wind M
ALTEX; 2010; 27(3):87-95. PubMed ID: 21113563
[TBL] [Abstract][Full Text] [Related]
6. Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA).
Tollefsen KE; Scholz S; Cronin MT; Edwards SW; de Knecht J; Crofton K; Garcia-Reyero N; Hartung T; Worth A; Patlewicz G
Regul Toxicol Pharmacol; 2014 Dec; 70(3):629-40. PubMed ID: 25261300
[TBL] [Abstract][Full Text] [Related]
7. Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes.
Patlewicz G; Simon TW; Rowlands JC; Budinsky RA; Becker RA
Regul Toxicol Pharmacol; 2015 Apr; 71(3):463-77. PubMed ID: 25707856
[TBL] [Abstract][Full Text] [Related]
8. Towards an integrated in vitro strategy for repeated dose toxicity testing.
Vanhaecke T; Pauwels M; Vinken M; Ceelen L; Rogiers V
Arch Toxicol; 2011 May; 85(5):365-6. PubMed ID: 21512801
[No Abstract] [Full Text] [Related]
9. Adverse outcome pathways: From research to regulation scientific workshop report.
Kleinstreuer NC; Sullivan K; Allen D; Edwards S; Mendrick DL; Embry M; Matheson J; Rowlands JC; Munn S; Maull E; Casey W
Regul Toxicol Pharmacol; 2016 Apr; 76():39-50. PubMed ID: 26774756
[TBL] [Abstract][Full Text] [Related]
10. Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale.
Halappanavar S; van den Brule S; Nymark P; Gaté L; Seidel C; Valentino S; Zhernovkov V; Høgh Danielsen P; De Vizcaya A; Wolff H; Stöger T; Boyadziev A; Poulsen SS; Sørli JB; Vogel U
Part Fibre Toxicol; 2020 May; 17(1):16. PubMed ID: 32450889
[TBL] [Abstract][Full Text] [Related]
11. Chemical hazard prediction and hypothesis testing using quantitative adverse outcome pathways.
Perkins EJ; Gayen K; Shoemaker JE; Antczak P; Burgoon L; Falciani F; Gutsell S; Hodges G; Kienzler A; Knapen D; McBride M; Willett C; Doyle FJ; Garcia-Reyero N
ALTEX; 2019; 36(1):91-102. PubMed ID: 30332685
[TBL] [Abstract][Full Text] [Related]
12. The current status of exposure-driven approaches for chemical safety assessment: A cross-sector perspective.
Sewell F; Aggarwal M; Bachler G; Broadmeadow A; Gellatly N; Moore E; Robinson S; Rooseboom M; Stevens A; Terry C; Burden N
Toxicology; 2017 Aug; 389():109-117. PubMed ID: 28774667
[TBL] [Abstract][Full Text] [Related]
13. [Challenge for Adverse Outcome Pathway (AOP)-based Chemical Safety Assessment].
Yamada T; Ashikaga T; Kojima H; Hirose A
Yakugaku Zasshi; 2020; 140(4):481-484. PubMed ID: 32238628
[TBL] [Abstract][Full Text] [Related]
14. SEURAT: Safety Evaluation Ultimately Replacing Animal Testing--recommendations for future research in the field of predictive toxicology.
Daston G; Knight DJ; Schwarz M; Gocht T; Thomas RS; Mahony C; Whelan M
Arch Toxicol; 2015 Jan; 89(1):15-23. PubMed ID: 25433540
[TBL] [Abstract][Full Text] [Related]
15. The potential of AOP networks for reproductive and developmental toxicity assay development.
Knapen D; Vergauwen L; Villeneuve DL; Ankley GT
Reprod Toxicol; 2015 Aug; 56():52-5. PubMed ID: 25889759
[TBL] [Abstract][Full Text] [Related]
16. Use and validation of HT/HC assays to support 21st century toxicity evaluations.
Patlewicz G; Simon T; Goyak K; Phillips RD; Rowlands JC; Seidel SD; Becker RA
Regul Toxicol Pharmacol; 2013 Mar; 65(2):259-68. PubMed ID: 23291301
[TBL] [Abstract][Full Text] [Related]
17. Adverse outcome pathway development from protein alkylation to liver fibrosis.
Horvat T; Landesmann B; Lostia A; Vinken M; Munn S; Whelan M
Arch Toxicol; 2017 Apr; 91(4):1523-1543. PubMed ID: 27542122
[TBL] [Abstract][Full Text] [Related]
18. Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals.
Murugadoss S; Vinković Vrček I; Schaffert A; Paparella M; Pem B; Sosnowska A; Stępnik M; Martens M; Willighagen EL; Puzyn T; Roxana Cimpan M; Lemaire F; Mertens B; Dusinska M; Fessard V; Hoet PH
ALTEX; 2024 Jan; 41(1):76-90. PubMed ID: 37606097
[TBL] [Abstract][Full Text] [Related]
19. Toxicology in the 21st century--working our way towards a visionary reality.
Berg N; De Wever B; Fuchs HW; Gaca M; Krul C; Roggen EL
Toxicol In Vitro; 2011 Jun; 25(4):874-81. PubMed ID: 21338664
[TBL] [Abstract][Full Text] [Related]
20. Current perspectives on the use of alternative species in human health and ecological hazard assessments.
Perkins EJ; Ankley GT; Crofton KM; Garcia-Reyero N; LaLone CA; Johnson MS; Tietge JE; Villeneuve DL
Environ Health Perspect; 2013 Sep; 121(9):1002-10. PubMed ID: 23771518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
